Use of antifibrosis agents and glaucoma drainage devices in the American and Japanese Glaucoma Societies.
OBJECTIVE
To investigate practice patterns among glaucoma subspecialists in the American Glaucoma Society (AGS) and the Japanese Glaucoma Society (JGS), regarding use of antifibrosis agents and glaucoma drainage devices.


METHODS
An anonymous survey incorporating 10 clinical situations was mailed to all AGS and JGS members in December 1995.


RESULTS
Half of the AGS (105 of 210), and JGS (25 of 50) members returned surveys. Most respondents (51-87%) preferred trabeculectomy with adjunctive mitomycin for all 10 clinical situations. Mitomycin concentrations varied from 0.1 to 0.8 mg/ml (range of means for 10 situations 0.31-0.39 mg/ml) and intraoperative application times ranged from 5 s to 7 min (range of means for 10 situations 2.5-4.6 min). Preferences for either no antifibrosis agent (up to 39%) or 5-fluorouracil (up to 29%) were highest in primary trabeculectomy. Thirty-seven percent to 64% of AGS members used glaucoma drainage devices, especially after complicated postsurgical glaucomas (after penetrating keratoplasty, scleral buckling, or pars plana vitrectomy) and in neovascular glaucoma, but few JGS members used them. Large differences between university- and private practice-based AGS members were found only in mitomycin use for primary trabeculectomy (33% vs. 52%, respectively; p = 0.07) and for complicated postsurgical glaucomas (46% vs. 70%, respectively; p = 0.03).


CONCLUSIONS
Trabeculectomy with mitomycin was the preferred surgical procedure among AGS and JGS members in the clinical situations surveyed. Mitomycin concentration and time of application varied widely. Many respondents used 5-fluorouracil or no antimetabolite in primary trabeculectomy. Glaucoma drainage devices were widely used for complicated glaucomas in the United States.
Chen
P P
PP
Bascom Palmer Eye Institute, University of Miami School of Medicine, Florida, USA.
Yamamoto
T
T
Sawada
A
A
Parrish
R K
RK
Kitazawa
Y
Y
D017024:Chemotherapy, Adjuvant; D003625:Data Collection; D004305:Dose-Response Relationship, Drug; D004322:Drainage / Q000295:instrumentation*; D005355:Fibrosis / Q000517:prevention & control; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D005901:Glaucoma / Q000628:therapy*; D006801:Humans; D007564:Japan; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D010818:Practice Patterns, Physicians'; D019736:Prostheses and Implants; D012189:Retrospective Studies; D012955:Societies, Medical; D014130:Trabeculectomy; D014481:United States
D008937:Mitomycins; D009883:Ophthalmic Solutions; D005472:Fluorouracil